Aslan Pharmaceuticals Ltd ADR (ASLN)

Aslan Pharmaceuticals (ASLN) Financial Statements


Aslan Pharmaceuticals Financial Overview

Aslan Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-3.005; its P/E ratio is -0.17; Aslan Pharmaceuticals is scheduled to report earnings on March 22, 2024, and the estimated EPS forecast is $-0.73. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Sep 22Jun 22Mar 22Dec 21
Income Statement-
Total Revenue-$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit---$ 0.00$ 0.00
EBIT-$ -9.97M$ -12.16M$ -11.85M$ -8.39M
EBITDA-$ -9.97M$ -12.16M$ -11.85M$ -8.39M
Net Income Common Stockholders-$ -10.93M$ -13.03M$ -12.94M$ -8.87M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 8.59K$ 68.95M$ 78.12M$ 87.40M$ 494.73K
Total Assets$ 61.19M$ 72.61M$ 80.61M$ 90.88M$ 4.35M
Total Debt$ 29.87M$ 36.64M$ 36.47M$ 36.54M$ 31.06M
Net Debt$ 29.86M$ -32.31M$ -41.65M$ -50.86M$ 30.56M
Total Liabilities$ 52.82M$ 50.55M$ 47.95M$ 45.80M$ 94.52M
Stockholders Equity$ 8.37M$ 22.06M$ 32.67M$ 45.07M$ -5.72M
Cash Flow-
Free Cash Flow-----
Operating Cash Flow-----
Investing Cash Flow-----
Financing Cash Flow-----
Currency in USD

Aslan Pharmaceuticals Earnings and Revenue History

Aslan Pharmaceuticals Debt to Assets

Aslan Pharmaceuticals Cash Flow

Aslan Pharmaceuticals Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis